{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T23:14:17Z","timestamp":1648768457588},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5-6","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Neurofibromatosis type 1 (NF1) is an autosomal dominant condition affecting 1 in 3,500 people resulting from an NF1 gene mutation that encodes the nonfunctional protein neurofibromin mutant. Neurofibromin is a negative regulator of RAS signaling involved in cell survival and proliferation. NF1 typically presents at birth or in early childhood with multiple light brown (caf\u00e9 au lait) spots and axillary freckling. With age, patients may develop scattered neurofibromas as well as additional neurological and malignant abnormalities. Additionally, the nonfunctional protein neurofibromin mutant may be involved in the pathogenesis of peripheral malignant nerve sheath tumors, which is a rare and life-threatening complication of NF1. While a disqualifying condition for military duty, it may not initially be clinically apparent until complications develop. Here, we present a case of malignant peripheral sheath in an U.S. Army African American reservist with NF1 in whom cutaneous manifestations of NF1 such as caf\u00e9 au lait spots and axillary freckling were not identified on the initial military entrance processing examination.<\/jats:p>","DOI":"10.1093\/milmed\/usaa458","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T18:38:35Z","timestamp":1605206315000},"page":"e626-e631","source":"Crossref","is-referenced-by-count":0,"title":["Malignant Peripheral Nerve Sheath Tumor in an Army Reservist With Neurofibromatosis Type 1"],"prefix":"10.1093","volume":"186","author":[{"given":"Chung-Ting J","family":"Kou","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Brooke Army Medical Center, TX 78234, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Rendo","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Brooke Army Medical Center, TX 78234, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin R","family":"Broadwater","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brooke Army Medical Center, TX 78234, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Beeler","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Brooke Army Medical Center, TX 78234, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"issue":"5","key":"2021050313324795400_R1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2021050313324795400_R2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s13311-017-0518-y","article-title":"Cancer of the peripheral nerve in neurofibromatosis type 1","volume":"14","author":"Staedtke","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"8","key":"2021050313324795400_R3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/s1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol"},{"issue":"5","key":"2021050313324795400_R4","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1988.00520290115023","article-title":"National Institutes of Health Consensus Development Conference. Neurofibromatosis","volume":"45","year":"1988","journal-title":"Arch Neurol"},{"issue":"7","key":"2021050313324795400_R5","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1172\/jci99424","article-title":"Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis","volume":"128","author":"Liao","year":"2018","journal-title":"J Clin Invest"},{"issue":"5","key":"2021050313324795400_R6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J Med Genet"},{"issue":"3","key":"2021050313324795400_R7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40477-014-0097-2","article-title":"Imaging of the malignant peripheral nerve sheath tumour with emphasis \u03bfn ultrasonography: correlation with MRI","volume":"17","author":"Rafailidis","year":"2014","journal-title":"J Ultrasound"},{"issue":"17","key":"2021050313324795400_R8","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1200\/jco.2015.65.3576","article-title":"Distinctive cancer associations in patients with neurofibromatosis type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"62","key":"2021050313324795400_R9","doi-asserted-by":"publisher","first-page":"104785","DOI":"10.18632\/oncotarget.18975","article-title":"Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: a retrospective study of 159 cases from 1999 to 2016","volume":"8","author":"Yuan","year":"2017","journal-title":"Oncotarget"},{"key":"2021050313324795400_R10","article-title":"Medical standards for appointment, enlistment, or induction in the Military services. DoD instruction 6130.03 2018: 36. Published 2018 May 6","author":"Under Secretary of Defense for Personnel and Readiness"},{"issue":"2","key":"2021050313324795400_R11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","article-title":"Malignant peripheral nerve sheath tumors","volume":"19","author":"Farid","year":"2014","journal-title":"Oncologist"},{"issue":"6","key":"2021050313324795400_R12","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.2214\/ajr.09.2724","article-title":"MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas","volume":"194","author":"Wasa","year":"2010","journal-title":"Am J Roentgenol"},{"issue":"1","key":"2021050313324795400_R13","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-016-0899-0","article-title":"Radiological findings of malignant peripheral nerve sheath tumor: reports of six cases and review of literature","volume":"14","author":"Yu","year":"2016","journal-title":"World J Surg Oncol"},{"issue":"4","key":"2021050313324795400_R14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4103\/0971-3026.169447","article-title":"Telltale signs of peripheral neurogenic tumors on magnetic resonance imaging","volume":"25","author":"Kakkar","year":"2015","journal-title":"Indian J Radiol Imaging"},{"key":"2021050313324795400_R15","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6162182","article-title":"The role of [18F]FDG-PET\/CT in predicting malignant transformation of plexiform neurofibromas in neurofibromatosis-1","volume":"2016","author":"Tovmassian","year":"2016","journal-title":"Int J Surg Oncol"},{"key":"2021050313324795400_R16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","article-title":"Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1\u2014a consensus overview","volume":"67","author":"Miettinen","year":"2017","journal-title":"Hum Pathol"},{"issue":"6","key":"2021050313324795400_R17","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/neuonc\/noy013","article-title":"The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors","volume":"20","author":"Higham","year":"2018","journal-title":"Neuro Oncol"},{"issue":"8","key":"2021050313324795400_R18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx124","article-title":"Neurofibromatosis type 1-associated MPNST state of the science: outlining a research agenda for the future","volume":"109","author":"Reilly","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2021050313324795400_R19","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8685638","article-title":"SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy-naive malignant peripheral nerve sheath tumors","volume":"2017","author":"Higham","year":"2017","journal-title":"Sarcoma"},{"issue":"1","key":"2021050313324795400_R20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/annonc\/mdq338","article-title":"First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other his-tological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study","volume":"22","author":"Kroep","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"2021050313324795400_R21","doi-asserted-by":"publisher","DOI":"10.4076\/1757-1626-2-7612","article-title":"Malignant peripheral nerve sheath tumor in neurobifromatosis type-1: two case reports","volume":"2","author":"Kosmas","year":"2009","journal-title":"Cases J"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/5-6\/e626\/37774654\/usaa458.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/5-6\/e626\/37774654\/usaa458.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T13:34:50Z","timestamp":1620048890000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/186\/5-6\/e626\/5979504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":21,"journal-issue":{"issue":"5-6","published-online":{"date-parts":[[2021,5,3]]},"published-print":{"date-parts":[[2021,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usaa458","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,5,1]]}}}